1-7 of 7
Markus Niggli
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial

Clinical Trials & Observations
Steven W. Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Sonia Deb, Markus Niggli, Tiffany Chang, Michaela Lehle, Karin Fijnvandraat
Journal: Blood
Blood (2024) 143 (14): 1355–1364.
https://doi.org/10.1182/blood.2023021832
Published: 2024
Includes: Supplemental data
Journal Articles

Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study

Steven Pipe, Peter Collins, Christophe Dhalluin, Gili Kenet, Christophe Schmitt, Muriel Buri, Víctor Jiménez-Yuste, Flora Peyvandi, Guy Young, Johannes Oldenburg, Maria Elisa Mancuso, Kaan Kavakli, Anna Kiialainen, Tiffany Chang, Michaela Lehle, Markus Niggli, Karin Fijnvandraat
Journal: Blood
Blood (2023) 142 (Supplement 1): 505.
https://doi.org/10.1182/blood-2023-177963
Published: 2023
Journal Articles

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Clinical Trials & Observations
Michael U. Callaghan, Claude Negrier, Ido Paz-Priel, Tiffany Chang, Sammy Chebon, Michaela Lehle, Johnny Mahlangu, Guy Young, Rebecca Kruse-Jarres, Maria Elisa Mancuso, Markus Niggli, Monet Howard, Nives Selak Bienz, Midori Shima, Victor Jiménez-Yuste, Christophe Schmitt, Elina Asikanius, Gallia G. Levy, Steven W. Pipe, Johannes Oldenburg
Journal: Blood
Blood (2021) 137 (16): 2231–2242.
https://doi.org/10.1182/blood.2020009217
Published: 2021
Includes: Supplemental data
Journal Articles

Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4)

Michael U. Callaghan, MD, Claude Négrier, Ido Paz-Priel, MD, Tiffany Chang, Sammy Chebon, Michaela Lehle, Johnny Mahlangu, Guy Young, MD, Rebecca Kruse-Jarres, MD, Maria Elisa Mancuso, Markus Niggli, Peter Kuebler, Nives Selak Bienz, Midori Shima, MD, Victor Jimenez-Yuste, MDcal Degree. PhD, Christophe Schmitt, Elina Asikanius, Gallia Levy, Steven W. Pipe, MD, Johannes Oldenburg
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–5.
https://doi.org/10.1182/blood-2020-137438
Published: 2020
Journal Articles

Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3

Anna Kiialainen, PhD, Markus Niggli, PhD, Christine L. Kempton, MD MSc, Giancarlo Castaman, MD, Tiffany Y. Chang, MD MAS, Ido Paz-Priel, MD, Joanne I Adamkewicz, PhD, Gallia G. Levy, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 626.
https://doi.org/10.1182/blood-2019-123689
Published: 2019
Journal Articles

Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience

Michael Callaghan, MD, Benjamin Trzaskoma, MS, Richard H. Ko, MD, Lucy Lee, PharmD, Anisha M. Patel, PhD, Eunice Tzeng, PharmD, Michelle Lynn Shah, PharmD, Tiffany Y. Chang, MD MAS, Markus Niggli, PhD, Christophe Dhalluin, PhD, Johnny Mahlangu, MMed, FCPath
Journal: Blood
Blood (2019) 134 (Supplement_1): 2395.
https://doi.org/10.1182/blood-2019-123654
Published: 2019
Journal Articles

Preference for Emicizumab over Prior Factor Treatments: Results from the HAVEN 3 and HAVEN 4 Studies

Victor Jimenez-Yuste, Midori Shima, MD PhD, Ido Paz-Priel, Aric Parnes, Michaela Lehle, Adam Giermasz, Avrita Campinha-Bacote, Markus Niggli, Jerzy Windyga, Sammy Chebon, Peter Trask, Johnny Mahlangu, Steven Pipe, Johannes Oldenburg
Journal: Blood
Blood (2018) 132 (Supplement 1): 1187.
https://doi.org/10.1182/blood-2018-99-118132
Published: 2018